Lung cancer patients may not need lifelong immunotherapy

NCT ID NCT03469960

Completed Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated Jun 23, 2026 · Updated 21 times

Summary

This phase 3 trial tested whether patients with advanced PDL1-positive lung cancer could safely stop immunotherapy after 6 months instead of continuing until the disease worsens. 265 participants received a combination of nivolumab and ipilimumab, then were randomly assigned to either stop treatment and be monitored or continue the drugs. The goal was to see if stopping early is just as effective, while reducing side effects and improving quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

AP-HP Hopital Tenon - Pneumologie

Paris, 75020, France
AP-HP Hôpital Bichat

Paris, France
Amiens - CHU

Amiens, France
Angers - CHU

Angers, 49000, France
Annecy - CH

Annecy, 74374, France
Argenteuil -CH

Argenteuil, 95100, France
Avignon - CH

Avignon, France
Bordeaux - Polyclinique Nord

Bordeaux, France
Boulogne - Ambroise Paré

Boulogne-Billancourt, France
CH

Cholet, France
CH Chambery

Chambéry, France
CH Lyon Sud - Pneumologie

Lyon, France
CH de Chauny

Chauny, France
CH de Pontoise

Cergy-Pontoise, France
CH de Villefranche - Pneumologie

Villefranche, France
CHRU Grenoble

Grenoble, France
CHRU de Lille

Lille, France
CHRU de Tours

Tours, France
CHU Nîmes

Nîmes, France
CHU Toulouse

Toulouse, France
CHU de Limoges

Limoges, France
Caen - CHU Côte de Nacre

Caen, 14000, France
Cahors - CH

Cahors, 46000, France
Centre Antoine Lacassagne

Nice, France
Centre Hospitalier - Pneumologie

Le Mans, 72000, France
Centre René Huguenin

Saint-Cloud, France
Clamart - Hôpital Percy

Clamart, 92140, France
Clermont Ferrand - CHU

Clermont-Ferrand, 63000, France
Colmar - CH

Colmar, 68000, France
Dijon - CAC

Dijon, 21000, France
GH Paris Saint-Joseph

Paris, France
HIA Begin

Saint-Mandé, France
Hôpital Saint Louis APHP

Paris, France
ICL Lucien Neuwirth

Saint-Priest-en-Jarez, France
Institut Paoli Calmette

Marseille, France
La Roche Sur Yon - CH

La Roche-sur-Yon, 85925, France
Marseille - Hôpital Européen

Marseille, France
Mont de Marsan - CH

Mont-de-Marsan, 40000, France
Mulhouse - CH

Mulhouse, 68000, France
Nantes - Centre René Gauducheau

Nantes, 44805, France
Orléans - CH

Orléans, 45000, France
Paris - Institut Curie

Paris, France
Rouen - CHU

Rouen, 76000, France
Saint Quentin - CH

Saint-Quentin, 02100, France
Suresnes - Hopital Foch

Suresnes, 92151, France
Toulon - CHI

Toulon, 83000, France
Versailles - CH

Versailles, 78157, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Nivolumab and Ipilimumab (immunotherapy drugs)

What this could lead to

If successful, this could show that a shorter course of immunotherapy is as effective as continuous treatment, reducing side effects and improving quality of life for lung cancer patients.

What could go wrong

This is a completed phase 3 trial, but results may not apply to all patients. Stopping treatment early could risk disease progression in some individuals.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER METASTATIC NON SMALL CELL LUNG CANCER METASTATIC